ArticleCureus2025
Diagnostic Challenges in a Patient With Systemic Lupus Erythematosus (SLE) and Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-N-methyl-D-aspartate receptor encephalitis (NMDAR-E) is an autoimmune disorder characterized by psychiatric and neurological symptoms associated with the presence of anti-GluN1 antibodies in the cerebrospinal fluid (CSF). Neuropsychiatric systemic lupus erythematosus (NPSLE) encompasses 19 syndromes and remains a diagnostic challenge due to its heterogeneous clinical presentation and reliance on exclusion. While anti-GluN2 antibodies have been linked to systemic lupus erythematosus (SLE), the coexistence of NPSLE and NMDAR-E has been scarcely reported. Since the first case published in 2016, fewer than 15 patients have been documented worldwide, mostly as isolated case reports and only a few small series including patients with systemic autoimmune diseases such as SLE. We report a 31-year-old woman with a one-year history of SLE who developed neuropsychiatric manifestations initially attributed to NPSLE. Despite treatment with high-dose corticosteroids, cyclophosphamide, and antipsychotics, she experienced recurrent psychotic episodes with poor response. Brain magnetic resonance imaging (MRI) showed nonspecific hyperintense lesions, and CSF analysis revealed positive anti-GluN1 antibodies, confirming the diagnosis of NMDAR-E. The patient improved after intravenous immunoglobulin and plasmapheresis, and she remained stable under maintenance therapy with azathioprine and rituximab. This case illustrates the diagnostic complexity of neuropsychiatric manifestations in SLE, where overlapping autoimmunity may conceal the presence of NMDAR-E. Clinicians should maintain a high index of suspicion for autoimmune encephalitis in SLE patients with refractory neuropsychiatric symptoms, as timely recognition and treatment can significantly improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.